Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Прегравидарная подготовка, беременность и роды, особенности течения послеродового периода при рассеянном склерозе (обзор литературы)
Прегравидарная подготовка, беременность и роды, особенности течения послеродового периода при рассеянном склерозе (обзор литературы)
Купина А.Д., Петров Ю.А. Прегравидарная подготовка, беременность и роды, особенности течения послеродового периода при рассеянном склерозе (обзор литературы). Гинекология. 2020; 22 (2): e. 30.
DOI: 10.26442/20795696.2020.2.190711
DOI: 10.26442/20795696.2020.2.190711
DOI: 10.26442/20795696.2020.2.190711
________________________________________________
DOI: 10.26442/20795696.2020.2.190711
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Рассеянный склероз (РС) является хроническим аутоиммунным заболеванием, характеризующимся образованием очагов поражения в белом веществе мозга в результате аутоиммунного воспаления, нейродегенерации и демиелинизации и приводящим к тяжелой инвалидизации пациентов. Женщины болеют чаще, чем мужчины, около 2/3 всех пациентов с РС составляют молодые женщины репродуктивного возраста. Установлено, что беременность и роды при РС оказывают благоприятное воздействие на течение заболевания, однако пациенткам с РС необходима прегравидарная подготовка, которая позволит снизить риск развития обострений. Экзацербации наблюдаются в большинстве случаев в течение первых 3–6 мес послеродового периода, что связано с изменением гормонального статуса, эмоциональной и физической нагрузкой на организм женщины, а также с прекращением физиологической иммуносупрессии у беременной. Проведен анализ современных источников литературы, посвященных вопросам прегравидарной подготовки, беременности и родов, особенностей течения послеродового периода при рассеянном склерозе, а также новым представлениям об этиологии и патогенезе заболевания. Проанализировано 47 источников литературы (отечественных и зарубежных) с использованием различных баз данных (PubMed, PubMed Central, Google Scholar, UpToDate).
Ключевые слова: аутоиммунное воспаление, прегравидарная подготовка, послеродовой период, экзацербация.
Key words: autoimmune inflammation, pregravid preparation, postpartum period, exacerbation.
Ключевые слова: аутоиммунное воспаление, прегравидарная подготовка, послеродовой период, экзацербация.
________________________________________________
Key words: autoimmune inflammation, pregravid preparation, postpartum period, exacerbation.
Полный текст
Список литературы
1. Парфенов В.А., Яхно Н.Н., Евзиков Г.Ю. Нервные болезни. Учебник. М.: Медицинское информационное агентство, 2018.
[Parfenov V.A., Yakhno N.N., Evzikov G.Yu. Nervous Diseases. A Textbook. Moscow: Meditsinskoe informatsionnoe agentstvo, 2018 (in Russian).]
2. Морозова С.Н., Брюхов В.В., Трифонова О.В. и др. Поражение спинного мозга у пациентов с рассеянным склерозом после обострения по данным диффузионно-тензорной магнитно-резонансной томографии. Журн. неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2016; 116 (2): 21–6. https://doi.org/10.17116/jnevro20161162221-26
[Morozova S.N., Bryukhov V.V., Trifonova O.V. et al. A DTI study of the spinal cord lesion in patients with multiple sclerosis during the follow-up after relapse. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski. 2016; 116 (2): 21–6. https://doi.org/10.17116/jnevro20161162221-26 (in Russian).]
3. Прожерина Ю. Рассеянный склероз: история, диагностика, лечение. Ремедиум. 2016; 8 (7): 21–5.
[Prozherina Yu. Multiple sclerosis: history, diagnosis, treatment. Remedium. 2016; 8 (7): 21–5 (in Russian).]
4. Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease. Saunders Elsevier Publ 2014; p. 1473–5.
5. Malik O, Donnelly A, Barnett М. Fast Facts Multiple Sclerosis. Health Press Ltd Publ. 2014; 136.
6. Fourcade J, Sun Z, Kudela P et al. Human tumor antigen-specific helper and regulatory T-cells share common epitope specificity but exhibit distinct T-cell repertoire. J Immunology 2010; 184 (12): 6709–18. https://doi.org/ 10.4049/jimmunol.0903612
7. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handbook Clin Neurol 2014; 122: 269–90.
https://doi.org/10.1016/B978-0-444-52001-2.00011-X
8. Mullin AP, Cui Ch,Wang Yu et al. rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination. Neurobiol Dis 2017; 105: 142–55. https://doi.org/10.1016/j.nbd.2017.05.015
9. Plemel JR, Liu WQ, Yong WV. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nature Reviews Drug Discovery 2017; 16: 617–34. https://doi.org/10.1038/nrd.2017.115
10. Губарев Ю.Д., Яценко Е.А., Чефранова Ж.Ю. Клиническая эффективность препарата «Азилект» в терапии вторично-прогрессирующего рассеянного склероза. Научный результат. 2015; 1 (4): 5–12. https://doi.org/10.18413/2313-8955-2015-1-4-5-12
[Gubarev Yu.D., Yatsenko E.A., Chefranova Zh.Yu. Clinical efficiency of Azilekt in the therapy of primary progressing multiple sclerosis. Nauchnyi rezul'tat. 2015; 1 (4): 5–12. https://doi.org/10.18413/2313-8955-2015-1-4-5-12 (in Russian).]
11. Alamouti MA, Bakhtiyari M, Moradi F et al. Remyelination of the corpus callosum by olfactory ensheathing cell in an experimental model of multiple sclerosis. Acta Medica Iranica 2015; 53 (9): 533–9.
12. Atlas of multiple sclerosis 2013. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
13. Баранов А.А., Намазова-Баранова Л.С. Атлас редких болезней. ФГБУ «Научный центр здоровья детей» РАМН. М.: ПедиатрЪ, 2013; c. 304.
[Baranov A.A., Namazova-Baranova L.S. Atlas of rare diseases. FSBI "Scientific Center for Children's Health" RAMS. Moscow: Pediatr"", 2013; p. 304 (in Russian).]
14. Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013; 80 (6): 548–52. https://doi.org/10.1212/WNL.0b013e3182a7af5f
15. Чжу М.Б. Коморбидность при рассеянном склерозе. Молодой ученый. 2018; 44: 225–7.
[Chzhu M.B. Multiple Sclerosis Comorbidity. Molodoi uchenyi. 2018; 44: 225–7 (in Russian).]
16. Ширинский В.С., Ширинский И.В. Коморбидные заболевания – актуальная проблема клинической медицины. Сиб. мед. журн. 2014; 29 (1): 7–12. https://doi.org/10.29001/2073-8552-2014-29-1-7-12
[Shirinskii V.S., Shirinskii I.V. Comorbid diseases as an important problem of clinical medicine. Sib. med. zhurn. 2014; 29 (1): 7–12. https://doi.org/10.29001/2073-8552-2014-29-1-7-12 (in Russian).]
17. O'Gorman C, Bukhari W, Todd A et al. Smoking increases the risk of multiple sclerosis in Queensland, Australia. J Clin Neurosci 2014; 21 (10): 1730–3. https://doi.org/10.1016/j.jocn.2014.01.009
18. Wang Z, Sadovnick AD, Traboulsee AL et al. Nuclear Receptor NR1H3 in Familial Multiple Sclerosis. Neuron 2016; 92 (2): 555. https://doi.org/10.1016/j.neuron.2016.09.028
19. Ghasemi N, Razavi Sh, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell Journal 2017; 19 (1): 1–10. https://doi.org/10.22074/cellj.2016.4867
20. Коробко Д.С., Малкова Н.А., Соколова Е.А., Филипенко М.Л. Фенотип и генотип семейного рассеянного склероза. Медицина и образование в Сибири. 2012; 6. http://ngmu.ru/cozo/mos/article/text_full.php?id=853
[Korobko D.S., Malkova N.A., Sokolova E.A., Filipenko M.L. Phenotype and genotype of familial multiple sclerosis1cbgh. Meditsina i obrazovanie v Sibiri. 2012; 6 (in Russian).]
21. Bäärnhielm M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Multiple Sclerosis J 2014; 20 (6): 726–32. https://doi.org/10.1177/1352458513509508
22. Bilbaoa MM, Durána SB, Llonaa JB, Rodriguez-Antigüedad A. Multiple sclerosis: pregnancy and women's health issues. Neurologia 2019; 34 (4): 259–69. https://doi.org/10.1016/j.nrleng.2016.06.014
23. Шарова И.В., Куташов В.А. Рассеянный склероз, беременность и роды. Медицина: вызовы сегодняшнего дня: материалы III Международной научной конференции. М.: Буки-Веди, 2016; c. 57–60.
[Sharova I.V., Kutashov V.A. Multiple sclerosis, pregnancy and childbirth. Medicine: today's challenges: proceedings of the III International Scientific Conference. Moscow: Buki-Vedi, 2016; p. 57–60 (in Russian).]
24. Тихоновская О.А., Кочеткова А.Ю., Алифирова В.М. Особенности репродуктивного здоровья женщин, больных рассеянным склерозом. Acta Biomedica Scientifica. 2017; 2 (5): 26–31.
[Tikhonovskaya O.A., Kochetkova A.Yu., Alifirova V.M. The features of reproductive health in women with multiple sclerosis. Acta Biomedica Scientifica. 2017; 2 (5): 26–31 (in Russian).]
25. McCombe PA. The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. J Clin Med 2018; 7 (12): 494. https://doi.org/10.3390/jcm7120494
26. Якушина Т.И., Котов С.В., Якушин М.А. Анализ течения беременности, родов и послеродового периода у женщин с рассеянным склерозом. Альманах клинической медицины. 2015; 39: 82–8. https://doi.org/10.18786/2072-0505-2015-39-82-89
[Yakushina T.I., Kotov S.V., Yakushin M.A. Analysis of the course of pregnancy, delivery and postpartum period in women with multiple sclerosis. Al'manakh klinicheskoi meditsiny. 2015; 39: 82–8. https://doi.org/10.18786/2072-0505-2015-39-82-89 (in Russian).]
27. Шмидт Т.Е. Ранняя диагностика рассеянного склероза. Рус. мед. журн. Неврология. 2010; 18 (5): 224.
[Shmidt T.E. Early diagnosis of multiple sclerosis. Rus. med. zhurn. Nevrologiya. 2010; 18 (5): 224 (in Russian).]
28. Карнаух В.Н., Барабаш И.А. Является ли беременность фактором риска рассеянного склероза? Влияние на прогноз. Дальневосточный мед. журн. 2010; 1: 131–4.
[Karnaukh V.N., Barabash I.A. Is pregnancy a risk factor of multiple sclerosis? Its influence on the prognosis of the disease. Dal'nevostochnyi med. zhurn. 2010; 1: 131–4 (in Russian).]
29. Радзинский В.Е., Фукс А.М. Гинекология. Учебник. М.: ГЭОТАР-Медиа, 2014.
[Radzinskii V.E., Fuks A.M. Gynecology. A textbook. Moscow: GEOTAR-Media, 2014 (in Russian).]
30. Шмидт Т.Е., Яхно Н.Н.. Рассеянный склероз. Руководство для врачей. М.: МЕДпресс-информ, 2016.
[Shmidt TE, Yakhno NN. Multiple sclerosis: a guideline. Moscow: MEDpress-inform, 2016 (in Russian).]
31. Houtchens MK, Edwards NC, Schneider G et al. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology 2018; 91 (17): e1559–e1569. https://doi.org/10.1212/WNL.0000000000006384
32. Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-b1a in relapsing-remitting multiple sclerosis. CNS Drugs 2015; 29 (1): 71–81. https://doi.org/10.1007/s40263-014-0207-x
33. Alwan S, Yee I, Dybalski M et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Multiple Sclerosis J 2013; 19: 351–8. https://doi.org/10.1177/1352458512452920
34. Hutchinson M, Fox RJ, Havrdova E et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Cur Med Res Opin 2014; 30 (4): 613–27. https://doi.org/10.1185/03007995.2013.863755
35. Спирин Н.Н., Касаткин Д.С., Степанов И.О. и др. Побочные эффекты терапии препаратами, изменяющими течение рассеянного склероза (ПИТРС), по данным регистра рассеянного склероза Ярославской области. Журн. неврологии и психиатрии им. С.С. Корсакова. 2012; 112 (8): 27–33.
[Spirin N.N., Kasatkin D.S., Stepanov I.O. et al. Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2012; 112 (8): 27–33 (in Russian).]
36. Lu E, Wang BW, Guimond C et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Exp Rev Neurotherapeutics 2013; 13 (3): 251–60. https://doi.org/10.1586/ern.13.12
37. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clinical Risk Management 2016; 12: 339–50. https://doi.org/10.2147/TCRM.S85099
38. Tavazzi E, Rovaris M, Mantia LL. Drug therapy for multiple sclerosis. Canadian Med Assoc J 2014; 186 (11): 833–40. https://doi.org/10.1503/cmaj.130727
39. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Multiple Sclerosis J 2013; 19: 835–43. https://doi.org/10.1177/1352458512471880
40. Sena A, Couderc R, Vasconcelos JC et al. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci 2012; 317 (1–2): 47–51. https://doi.org/10.1016/j.jns.2012.02.033
41. Gava G, Bartolomei I, Costantino A et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertil Steril 2014; 102 (1): 116–22. https://doi.org/10.1016/j.fertnstert.2014.03.054
42. Кочеткова А.Ю., Тихоновская О.А., Алифирова В.М. Влияние комбинированных оральных контрацептивов на течение рассеянного склероза. Современные проблемы науки и образования. 2015; 6. http://www.science-education.ru/ru/article/view?id=22818
[Kochetkova A.Yu., Tikhonovskaya O.A., Alifirova V.M. The effect of combined oral contraceptives on the course of multiple sclerosis. Sovremennye problemy nauki i obrazovaniya. 2015; (6). http://www.science-education.ru/ru/article/view?id=22818 (in Russian).]
43. Попова Е.В., Кукель Т.М., Муравин А.И. и др. Ретроспективный анализ течения беременности и родов у женщин с рассеянным склерозом. Журн. неврологии и психиатрии им. С.С. Корсакова. 2013; 113 (10): 52–6.
[Popova E.V., Kukel' T.M., Muravin A.I. et al. Pregnancy and delivery in women with multiple sclerosis: a retrospective analysis. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2013; 113 (10): 52–6 (in Russian).]
44. Finkelsztejn A, Brooks JBB, Paschoal FM, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and metaanalysis of the literature. BJOG 2011; 118 (7): 790–7. https://doi.org/10.1111/j.1471-0528.2011.02931.x
45. Муравин А.И., Бойко А.Н., Попова Е.В., Мурашко А.В. Влияние беременности на течение рассеянного склероза. Мед. совет. 2015; 7: 23–7.
[Muravin A.I., Boiko A.N., Popova E.V., Murashko A.V. Effect of pregnancy on the course of multiple sclerosis. Med. sovet. 2015; 7: 23–7 (in Russian).]
2. Morozova S.N., Bryukhov V.V., Trifonova O.V. et al. A DTI study of the spinal cord lesion in patients with multiple sclerosis during the follow-up after relapse. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski. 2016; 116 (2): 21–6. https://doi.org/10.17116/jnevro20161162221-26 (in Russian).
3. Prozherina Yu. Multiple sclerosis: history, diagnosis, treatment. Remedium. 2016; 8 (7): 21–5 (in Russian).
4. Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease. Saunders Elsevier Publ 2014; p. 1473–5.
5. Malik O, Donnelly A, Barnett М. Fast Facts Multiple Sclerosis. Health Press Ltd Publ. 2014; 136.
6. Fourcade J, Sun Z, Kudela P et al. Human tumor antigen-specific helper and regulatory T-cells share common epitope specificity but exhibit distinct T-cell repertoire. J Immunology 2010; 184 (12): 6709–18. https://doi.org/ 10.4049/jimmunol.0903612
7. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handbook Clin Neurol 2014; 122: 269–90.
https://doi.org/10.1016/B978-0-444-52001-2.00011-X
8. Mullin AP, Cui Ch,Wang Yu et al. rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination. Neurobiol Dis 2017; 105: 142–55. https://doi.org/10.1016/j.nbd.2017.05.015
9. Plemel JR, Liu WQ, Yong WV. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nature Reviews Drug Discovery 2017; 16: 617–34. https://doi.org/10.1038/nrd.2017.115
10. Gubarev Yu.D., Yatsenko E.A., Chefranova Zh.Yu. Clinical efficiency of Azilekt in the therapy of primary progressing multiple sclerosis. Nauchnyi rezul'tat. 2015; 1 (4): 5–12. https://doi.org/10.18413/2313-8955-2015-1-4-5-12 (in Russian).
11. Alamouti MA, Bakhtiyari M, Moradi F et al. Remyelination of the corpus callosum by olfactory ensheathing cell in an experimental model of multiple sclerosis. Acta Medica Iranica 2015; 53 (9): 533–9.
12. Atlas of multiple sclerosis 2013. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
13. Baranov A.A., Namazova-Baranova L.S. Atlas of rare diseases. FSBI "Scientific Center for Children's Health" RAMS. Moscow: Pediatr"", 2013; p. 304 (in Russian).
14. Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013; 80 (6): 548–52. https://doi.org/10.1212/WNL.0b013e3182a7af5f
15. Chzhu M.B. Multiple Sclerosis Comorbidity. Molodoi uchenyi. 2018; 44: 225–7 (in Russian).
16. Shirinskii V.S., Shirinskii I.V. Comorbid diseases as an important problem of clinical medicine. Sib. med. zhurn. 2014; 29 (1): 7–12. https://doi.org/10.29001/2073-8552-2014-29-1-7-12 (in Russian).
17. O'Gorman C, Bukhari W, Todd A et al. Smoking increases the risk of multiple sclerosis in Queensland, Australia. J Clin Neurosci 2014; 21 (10): 1730–3. https://doi.org/10.1016/j.jocn.2014.01.009
18. Wang Z, Sadovnick AD, Traboulsee AL et al. Nuclear Receptor NR1H3 in Familial Multiple Sclerosis. Neuron 2016; 92 (2): 555. https://doi.org/10.1016/j.neuron.2016.09.028
19. Ghasemi N, Razavi Sh, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell Journal 2017; 19 (1): 1–10. https://doi.org/10.22074/cellj.2016.4867
20. Korobko D.S., Malkova N.A., Sokolova E.A., Filipenko M.L. Phenotype and genotype of familial multiple sclerosis1cbgh. Meditsina i obrazovanie v Sibiri. 2012; 6 (in Russian).
21. Bäärnhielm M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Multiple Sclerosis J 2014; 20 (6): 726–32. https://doi.org/10.1177/1352458513509508
22. Bilbaoa MM, Durána SB, Llonaa JB, Rodriguez-Antigüedad A. Multiple sclerosis: pregnancy and women's health issues. Neurologia 2019; 34 (4): 259–69. https://doi.org/10.1016/j.nrleng.2016.06.014
23. Sharova I.V., Kutashov V.A. Multiple sclerosis, pregnancy and childbirth. Medicine: today's challenges: proceedings of the III International Scientific Conference. Moscow: Buki-Vedi, 2016; p. 57–60 (in Russian).
24. Tikhonovskaya O.A., Kochetkova A.Yu., Alifirova V.M. The features of reproductive health in women with multiple sclerosis. Acta Biomedica Scientifica. 2017; 2 (5): 26–31 (in Russian).
25. McCombe PA. The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. J Clin Med 2018; 7 (12): 494. https://doi.org/10.3390/jcm7120494
26. Yakushina T.I., Kotov S.V., Yakushin M.A. Analysis of the course of pregnancy, delivery and postpartum period in women with multiple sclerosis. Al'manakh klinicheskoi meditsiny. 2015; 39: 82–8. https://doi.org/10.18786/2072-0505-2015-39-82-89 (in Russian).
27. Shmidt T.E. Early diagnosis of multiple sclerosis. Rus. med. zhurn. Nevrologiya. 2010; 18 (5): 224 (in Russian).
28. Karnaukh V.N., Barabash I.A. Is pregnancy a risk factor of multiple sclerosis? Its influence on the prognosis of the disease. Dal'nevostochnyi med. zhurn. 2010; 1: 131–4 (in Russian).
29. Radzinskii V.E., Fuks A.M. Gynecology. A textbook. Moscow: GEOTAR-Media, 2014 (in Russian).
30. Shmidt TE, Yakhno NN. Multiple sclerosis: a guideline. Moscow: MEDpress-inform, 2016 (in Russian).
31. Houtchens MK, Edwards NC, Schneider G et al. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology 2018; 91 (17): e1559–e1569. https://doi.org/10.1212/WNL.0000000000006384
32. Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-b1a in relapsing-remitting multiple sclerosis. CNS Drugs 2015; 29 (1): 71–81. https://doi.org/10.1007/s40263-014-0207-x
33. Alwan S, Yee I, Dybalski M et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Multiple Sclerosis J 2013; 19: 351–8. https://doi.org/10.1177/1352458512452920
34. Hutchinson M, Fox RJ, Havrdova E et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Cur Med Res Opin 2014; 30 (4): 613–27. https://doi.org/10.1185/03007995.2013.863755
35. Spirin N.N., Kasatkin D.S., Stepanov I.O. et al. Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2012; 112 (8): 27–33 (in Russian).
36. Lu E, Wang BW, Guimond C et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Exp Rev Neurotherapeutics 2013; 13 (3): 251–60. https://doi.org/10.1586/ern.13.12
37. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clinical Risk Management 2016; 12: 339–50. https://doi.org/10.2147/TCRM.S85099
38. Tavazzi E, Rovaris M, Mantia LL. Drug therapy for multiple sclerosis. Canadian Med Assoc J 2014; 186 (11): 833–40. https://doi.org/10.1503/cmaj.130727
39. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Multiple Sclerosis J 2013; 19: 835–43. https://doi.org/10.1177/1352458512471880
40. Sena A, Couderc R, Vasconcelos JC et al. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci 2012; 317 (1–2): 47–51. https://doi.org/10.1016/j.jns.2012.02.033
41. Gava G, Bartolomei I, Costantino A et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertil Steril 2014; 102 (1): 116–22. https://doi.org/10.1016/j.fertnstert.2014.03.054
42. Kochetkova A.Yu., Tikhonovskaya O.A., Alifirova V.M. The effect of combined oral contraceptives on the course of multiple sclerosis. Sovremennye problemy nauki i obrazovaniya. 2015; (6). http://www.science-education.ru/ru/article/view?id=22818 (in Russian).
43. Popova E.V., Kukel' T.M., Muravin A.I. et al. Pregnancy and delivery in women with multiple sclerosis: a retrospective analysis. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2013; 113 (10): 52–6 (in Russian).
44. Finkelsztejn A, Brooks JBB, Paschoal FM, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and metaanalysis of the literature. BJOG 2011; 118 (7): 790–7. https://doi.org/10.1111/j.1471-0528.2011.02931.x
45. Muravin A.I., Boiko A.N., Popova E.V., Murashko A.V. Effect of pregnancy on the course of multiple sclerosis. Med. sovet. 2015; 7: 23–7 (in Russian).
[Parfenov V.A., Yakhno N.N., Evzikov G.Yu. Nervous Diseases. A Textbook. Moscow: Meditsinskoe informatsionnoe agentstvo, 2018 (in Russian).]
2. Морозова С.Н., Брюхов В.В., Трифонова О.В. и др. Поражение спинного мозга у пациентов с рассеянным склерозом после обострения по данным диффузионно-тензорной магнитно-резонансной томографии. Журн. неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2016; 116 (2): 21–6. https://doi.org/10.17116/jnevro20161162221-26
[Morozova S.N., Bryukhov V.V., Trifonova O.V. et al. A DTI study of the spinal cord lesion in patients with multiple sclerosis during the follow-up after relapse. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski. 2016; 116 (2): 21–6. https://doi.org/10.17116/jnevro20161162221-26 (in Russian).]
3. Прожерина Ю. Рассеянный склероз: история, диагностика, лечение. Ремедиум. 2016; 8 (7): 21–5.
[Prozherina Yu. Multiple sclerosis: history, diagnosis, treatment. Remedium. 2016; 8 (7): 21–5 (in Russian).]
4. Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease. Saunders Elsevier Publ 2014; p. 1473–5.
5. Malik O, Donnelly A, Barnett М. Fast Facts Multiple Sclerosis. Health Press Ltd Publ. 2014; 136.
6. Fourcade J, Sun Z, Kudela P et al. Human tumor antigen-specific helper and regulatory T-cells share common epitope specificity but exhibit distinct T-cell repertoire. J Immunology 2010; 184 (12): 6709–18. https://doi.org/ 10.4049/jimmunol.0903612
7. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handbook Clin Neurol 2014; 122: 269–90.
https://doi.org/10.1016/B978-0-444-52001-2.00011-X
8. Mullin AP, Cui Ch,Wang Yu et al. rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination. Neurobiol Dis 2017; 105: 142–55. https://doi.org/10.1016/j.nbd.2017.05.015
9. Plemel JR, Liu WQ, Yong WV. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nature Reviews Drug Discovery 2017; 16: 617–34. https://doi.org/10.1038/nrd.2017.115
10. Губарев Ю.Д., Яценко Е.А., Чефранова Ж.Ю. Клиническая эффективность препарата «Азилект» в терапии вторично-прогрессирующего рассеянного склероза. Научный результат. 2015; 1 (4): 5–12. https://doi.org/10.18413/2313-8955-2015-1-4-5-12
[Gubarev Yu.D., Yatsenko E.A., Chefranova Zh.Yu. Clinical efficiency of Azilekt in the therapy of primary progressing multiple sclerosis. Nauchnyi rezul'tat. 2015; 1 (4): 5–12. https://doi.org/10.18413/2313-8955-2015-1-4-5-12 (in Russian).]
11. Alamouti MA, Bakhtiyari M, Moradi F et al. Remyelination of the corpus callosum by olfactory ensheathing cell in an experimental model of multiple sclerosis. Acta Medica Iranica 2015; 53 (9): 533–9.
12. Atlas of multiple sclerosis 2013. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
13. Баранов А.А., Намазова-Баранова Л.С. Атлас редких болезней. ФГБУ «Научный центр здоровья детей» РАМН. М.: ПедиатрЪ, 2013; c. 304.
[Baranov A.A., Namazova-Baranova L.S. Atlas of rare diseases. FSBI "Scientific Center for Children's Health" RAMS. Moscow: Pediatr"", 2013; p. 304 (in Russian).]
14. Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013; 80 (6): 548–52. https://doi.org/10.1212/WNL.0b013e3182a7af5f
15. Чжу М.Б. Коморбидность при рассеянном склерозе. Молодой ученый. 2018; 44: 225–7.
[Chzhu M.B. Multiple Sclerosis Comorbidity. Molodoi uchenyi. 2018; 44: 225–7 (in Russian).]
16. Ширинский В.С., Ширинский И.В. Коморбидные заболевания – актуальная проблема клинической медицины. Сиб. мед. журн. 2014; 29 (1): 7–12. https://doi.org/10.29001/2073-8552-2014-29-1-7-12
[Shirinskii V.S., Shirinskii I.V. Comorbid diseases as an important problem of clinical medicine. Sib. med. zhurn. 2014; 29 (1): 7–12. https://doi.org/10.29001/2073-8552-2014-29-1-7-12 (in Russian).]
17. O'Gorman C, Bukhari W, Todd A et al. Smoking increases the risk of multiple sclerosis in Queensland, Australia. J Clin Neurosci 2014; 21 (10): 1730–3. https://doi.org/10.1016/j.jocn.2014.01.009
18. Wang Z, Sadovnick AD, Traboulsee AL et al. Nuclear Receptor NR1H3 in Familial Multiple Sclerosis. Neuron 2016; 92 (2): 555. https://doi.org/10.1016/j.neuron.2016.09.028
19. Ghasemi N, Razavi Sh, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell Journal 2017; 19 (1): 1–10. https://doi.org/10.22074/cellj.2016.4867
20. Коробко Д.С., Малкова Н.А., Соколова Е.А., Филипенко М.Л. Фенотип и генотип семейного рассеянного склероза. Медицина и образование в Сибири. 2012; 6. http://ngmu.ru/cozo/mos/article/text_full.php?id=853
[Korobko D.S., Malkova N.A., Sokolova E.A., Filipenko M.L. Phenotype and genotype of familial multiple sclerosis1cbgh. Meditsina i obrazovanie v Sibiri. 2012; 6 (in Russian).]
21. Bäärnhielm M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Multiple Sclerosis J 2014; 20 (6): 726–32. https://doi.org/10.1177/1352458513509508
22. Bilbaoa MM, Durána SB, Llonaa JB, Rodriguez-Antigüedad A. Multiple sclerosis: pregnancy and women's health issues. Neurologia 2019; 34 (4): 259–69. https://doi.org/10.1016/j.nrleng.2016.06.014
23. Шарова И.В., Куташов В.А. Рассеянный склероз, беременность и роды. Медицина: вызовы сегодняшнего дня: материалы III Международной научной конференции. М.: Буки-Веди, 2016; c. 57–60.
[Sharova I.V., Kutashov V.A. Multiple sclerosis, pregnancy and childbirth. Medicine: today's challenges: proceedings of the III International Scientific Conference. Moscow: Buki-Vedi, 2016; p. 57–60 (in Russian).]
24. Тихоновская О.А., Кочеткова А.Ю., Алифирова В.М. Особенности репродуктивного здоровья женщин, больных рассеянным склерозом. Acta Biomedica Scientifica. 2017; 2 (5): 26–31.
[Tikhonovskaya O.A., Kochetkova A.Yu., Alifirova V.M. The features of reproductive health in women with multiple sclerosis. Acta Biomedica Scientifica. 2017; 2 (5): 26–31 (in Russian).]
25. McCombe PA. The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. J Clin Med 2018; 7 (12): 494. https://doi.org/10.3390/jcm7120494
26. Якушина Т.И., Котов С.В., Якушин М.А. Анализ течения беременности, родов и послеродового периода у женщин с рассеянным склерозом. Альманах клинической медицины. 2015; 39: 82–8. https://doi.org/10.18786/2072-0505-2015-39-82-89
[Yakushina T.I., Kotov S.V., Yakushin M.A. Analysis of the course of pregnancy, delivery and postpartum period in women with multiple sclerosis. Al'manakh klinicheskoi meditsiny. 2015; 39: 82–8. https://doi.org/10.18786/2072-0505-2015-39-82-89 (in Russian).]
27. Шмидт Т.Е. Ранняя диагностика рассеянного склероза. Рус. мед. журн. Неврология. 2010; 18 (5): 224.
[Shmidt T.E. Early diagnosis of multiple sclerosis. Rus. med. zhurn. Nevrologiya. 2010; 18 (5): 224 (in Russian).]
28. Карнаух В.Н., Барабаш И.А. Является ли беременность фактором риска рассеянного склероза? Влияние на прогноз. Дальневосточный мед. журн. 2010; 1: 131–4.
[Karnaukh V.N., Barabash I.A. Is pregnancy a risk factor of multiple sclerosis? Its influence on the prognosis of the disease. Dal'nevostochnyi med. zhurn. 2010; 1: 131–4 (in Russian).]
29. Радзинский В.Е., Фукс А.М. Гинекология. Учебник. М.: ГЭОТАР-Медиа, 2014.
[Radzinskii V.E., Fuks A.M. Gynecology. A textbook. Moscow: GEOTAR-Media, 2014 (in Russian).]
30. Шмидт Т.Е., Яхно Н.Н.. Рассеянный склероз. Руководство для врачей. М.: МЕДпресс-информ, 2016.
[Shmidt TE, Yakhno NN. Multiple sclerosis: a guideline. Moscow: MEDpress-inform, 2016 (in Russian).]
31. Houtchens MK, Edwards NC, Schneider G et al. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology 2018; 91 (17): e1559–e1569. https://doi.org/10.1212/WNL.0000000000006384
32. Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-b1a in relapsing-remitting multiple sclerosis. CNS Drugs 2015; 29 (1): 71–81. https://doi.org/10.1007/s40263-014-0207-x
33. Alwan S, Yee I, Dybalski M et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Multiple Sclerosis J 2013; 19: 351–8. https://doi.org/10.1177/1352458512452920
34. Hutchinson M, Fox RJ, Havrdova E et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Cur Med Res Opin 2014; 30 (4): 613–27. https://doi.org/10.1185/03007995.2013.863755
35. Спирин Н.Н., Касаткин Д.С., Степанов И.О. и др. Побочные эффекты терапии препаратами, изменяющими течение рассеянного склероза (ПИТРС), по данным регистра рассеянного склероза Ярославской области. Журн. неврологии и психиатрии им. С.С. Корсакова. 2012; 112 (8): 27–33.
[Spirin N.N., Kasatkin D.S., Stepanov I.O. et al. Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2012; 112 (8): 27–33 (in Russian).]
36. Lu E, Wang BW, Guimond C et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Exp Rev Neurotherapeutics 2013; 13 (3): 251–60. https://doi.org/10.1586/ern.13.12
37. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clinical Risk Management 2016; 12: 339–50. https://doi.org/10.2147/TCRM.S85099
38. Tavazzi E, Rovaris M, Mantia LL. Drug therapy for multiple sclerosis. Canadian Med Assoc J 2014; 186 (11): 833–40. https://doi.org/10.1503/cmaj.130727
39. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Multiple Sclerosis J 2013; 19: 835–43. https://doi.org/10.1177/1352458512471880
40. Sena A, Couderc R, Vasconcelos JC et al. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci 2012; 317 (1–2): 47–51. https://doi.org/10.1016/j.jns.2012.02.033
41. Gava G, Bartolomei I, Costantino A et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertil Steril 2014; 102 (1): 116–22. https://doi.org/10.1016/j.fertnstert.2014.03.054
42. Кочеткова А.Ю., Тихоновская О.А., Алифирова В.М. Влияние комбинированных оральных контрацептивов на течение рассеянного склероза. Современные проблемы науки и образования. 2015; 6. http://www.science-education.ru/ru/article/view?id=22818
[Kochetkova A.Yu., Tikhonovskaya O.A., Alifirova V.M. The effect of combined oral contraceptives on the course of multiple sclerosis. Sovremennye problemy nauki i obrazovaniya. 2015; (6). http://www.science-education.ru/ru/article/view?id=22818 (in Russian).]
43. Попова Е.В., Кукель Т.М., Муравин А.И. и др. Ретроспективный анализ течения беременности и родов у женщин с рассеянным склерозом. Журн. неврологии и психиатрии им. С.С. Корсакова. 2013; 113 (10): 52–6.
[Popova E.V., Kukel' T.M., Muravin A.I. et al. Pregnancy and delivery in women with multiple sclerosis: a retrospective analysis. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2013; 113 (10): 52–6 (in Russian).]
44. Finkelsztejn A, Brooks JBB, Paschoal FM, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and metaanalysis of the literature. BJOG 2011; 118 (7): 790–7. https://doi.org/10.1111/j.1471-0528.2011.02931.x
45. Муравин А.И., Бойко А.Н., Попова Е.В., Мурашко А.В. Влияние беременности на течение рассеянного склероза. Мед. совет. 2015; 7: 23–7.
[Muravin A.I., Boiko A.N., Popova E.V., Murashko A.V. Effect of pregnancy on the course of multiple sclerosis. Med. sovet. 2015; 7: 23–7 (in Russian).]
________________________________________________
2. Morozova S.N., Bryukhov V.V., Trifonova O.V. et al. A DTI study of the spinal cord lesion in patients with multiple sclerosis during the follow-up after relapse. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski. 2016; 116 (2): 21–6. https://doi.org/10.17116/jnevro20161162221-26 (in Russian).
3. Prozherina Yu. Multiple sclerosis: history, diagnosis, treatment. Remedium. 2016; 8 (7): 21–5 (in Russian).
4. Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease. Saunders Elsevier Publ 2014; p. 1473–5.
5. Malik O, Donnelly A, Barnett М. Fast Facts Multiple Sclerosis. Health Press Ltd Publ. 2014; 136.
6. Fourcade J, Sun Z, Kudela P et al. Human tumor antigen-specific helper and regulatory T-cells share common epitope specificity but exhibit distinct T-cell repertoire. J Immunology 2010; 184 (12): 6709–18. https://doi.org/ 10.4049/jimmunol.0903612
7. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handbook Clin Neurol 2014; 122: 269–90.
https://doi.org/10.1016/B978-0-444-52001-2.00011-X
8. Mullin AP, Cui Ch,Wang Yu et al. rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination. Neurobiol Dis 2017; 105: 142–55. https://doi.org/10.1016/j.nbd.2017.05.015
9. Plemel JR, Liu WQ, Yong WV. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nature Reviews Drug Discovery 2017; 16: 617–34. https://doi.org/10.1038/nrd.2017.115
10. Gubarev Yu.D., Yatsenko E.A., Chefranova Zh.Yu. Clinical efficiency of Azilekt in the therapy of primary progressing multiple sclerosis. Nauchnyi rezul'tat. 2015; 1 (4): 5–12. https://doi.org/10.18413/2313-8955-2015-1-4-5-12 (in Russian).
11. Alamouti MA, Bakhtiyari M, Moradi F et al. Remyelination of the corpus callosum by olfactory ensheathing cell in an experimental model of multiple sclerosis. Acta Medica Iranica 2015; 53 (9): 533–9.
12. Atlas of multiple sclerosis 2013. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
13. Baranov A.A., Namazova-Baranova L.S. Atlas of rare diseases. FSBI "Scientific Center for Children's Health" RAMS. Moscow: Pediatr"", 2013; p. 304 (in Russian).
14. Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013; 80 (6): 548–52. https://doi.org/10.1212/WNL.0b013e3182a7af5f
15. Chzhu M.B. Multiple Sclerosis Comorbidity. Molodoi uchenyi. 2018; 44: 225–7 (in Russian).
16. Shirinskii V.S., Shirinskii I.V. Comorbid diseases as an important problem of clinical medicine. Sib. med. zhurn. 2014; 29 (1): 7–12. https://doi.org/10.29001/2073-8552-2014-29-1-7-12 (in Russian).
17. O'Gorman C, Bukhari W, Todd A et al. Smoking increases the risk of multiple sclerosis in Queensland, Australia. J Clin Neurosci 2014; 21 (10): 1730–3. https://doi.org/10.1016/j.jocn.2014.01.009
18. Wang Z, Sadovnick AD, Traboulsee AL et al. Nuclear Receptor NR1H3 in Familial Multiple Sclerosis. Neuron 2016; 92 (2): 555. https://doi.org/10.1016/j.neuron.2016.09.028
19. Ghasemi N, Razavi Sh, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell Journal 2017; 19 (1): 1–10. https://doi.org/10.22074/cellj.2016.4867
20. Korobko D.S., Malkova N.A., Sokolova E.A., Filipenko M.L. Phenotype and genotype of familial multiple sclerosis1cbgh. Meditsina i obrazovanie v Sibiri. 2012; 6 (in Russian).
21. Bäärnhielm M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Multiple Sclerosis J 2014; 20 (6): 726–32. https://doi.org/10.1177/1352458513509508
22. Bilbaoa MM, Durána SB, Llonaa JB, Rodriguez-Antigüedad A. Multiple sclerosis: pregnancy and women's health issues. Neurologia 2019; 34 (4): 259–69. https://doi.org/10.1016/j.nrleng.2016.06.014
23. Sharova I.V., Kutashov V.A. Multiple sclerosis, pregnancy and childbirth. Medicine: today's challenges: proceedings of the III International Scientific Conference. Moscow: Buki-Vedi, 2016; p. 57–60 (in Russian).
24. Tikhonovskaya O.A., Kochetkova A.Yu., Alifirova V.M. The features of reproductive health in women with multiple sclerosis. Acta Biomedica Scientifica. 2017; 2 (5): 26–31 (in Russian).
25. McCombe PA. The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. J Clin Med 2018; 7 (12): 494. https://doi.org/10.3390/jcm7120494
26. Yakushina T.I., Kotov S.V., Yakushin M.A. Analysis of the course of pregnancy, delivery and postpartum period in women with multiple sclerosis. Al'manakh klinicheskoi meditsiny. 2015; 39: 82–8. https://doi.org/10.18786/2072-0505-2015-39-82-89 (in Russian).
27. Shmidt T.E. Early diagnosis of multiple sclerosis. Rus. med. zhurn. Nevrologiya. 2010; 18 (5): 224 (in Russian).
28. Karnaukh V.N., Barabash I.A. Is pregnancy a risk factor of multiple sclerosis? Its influence on the prognosis of the disease. Dal'nevostochnyi med. zhurn. 2010; 1: 131–4 (in Russian).
29. Radzinskii V.E., Fuks A.M. Gynecology. A textbook. Moscow: GEOTAR-Media, 2014 (in Russian).
30. Shmidt TE, Yakhno NN. Multiple sclerosis: a guideline. Moscow: MEDpress-inform, 2016 (in Russian).
31. Houtchens MK, Edwards NC, Schneider G et al. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology 2018; 91 (17): e1559–e1569. https://doi.org/10.1212/WNL.0000000000006384
32. Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-b1a in relapsing-remitting multiple sclerosis. CNS Drugs 2015; 29 (1): 71–81. https://doi.org/10.1007/s40263-014-0207-x
33. Alwan S, Yee I, Dybalski M et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Multiple Sclerosis J 2013; 19: 351–8. https://doi.org/10.1177/1352458512452920
34. Hutchinson M, Fox RJ, Havrdova E et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Cur Med Res Opin 2014; 30 (4): 613–27. https://doi.org/10.1185/03007995.2013.863755
35. Spirin N.N., Kasatkin D.S., Stepanov I.O. et al. Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2012; 112 (8): 27–33 (in Russian).
36. Lu E, Wang BW, Guimond C et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Exp Rev Neurotherapeutics 2013; 13 (3): 251–60. https://doi.org/10.1586/ern.13.12
37. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clinical Risk Management 2016; 12: 339–50. https://doi.org/10.2147/TCRM.S85099
38. Tavazzi E, Rovaris M, Mantia LL. Drug therapy for multiple sclerosis. Canadian Med Assoc J 2014; 186 (11): 833–40. https://doi.org/10.1503/cmaj.130727
39. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Multiple Sclerosis J 2013; 19: 835–43. https://doi.org/10.1177/1352458512471880
40. Sena A, Couderc R, Vasconcelos JC et al. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci 2012; 317 (1–2): 47–51. https://doi.org/10.1016/j.jns.2012.02.033
41. Gava G, Bartolomei I, Costantino A et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertil Steril 2014; 102 (1): 116–22. https://doi.org/10.1016/j.fertnstert.2014.03.054
42. Kochetkova A.Yu., Tikhonovskaya O.A., Alifirova V.M. The effect of combined oral contraceptives on the course of multiple sclerosis. Sovremennye problemy nauki i obrazovaniya. 2015; (6). http://www.science-education.ru/ru/article/view?id=22818 (in Russian).
43. Popova E.V., Kukel' T.M., Muravin A.I. et al. Pregnancy and delivery in women with multiple sclerosis: a retrospective analysis. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2013; 113 (10): 52–6 (in Russian).
44. Finkelsztejn A, Brooks JBB, Paschoal FM, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and metaanalysis of the literature. BJOG 2011; 118 (7): 790–7. https://doi.org/10.1111/j.1471-0528.2011.02931.x
45. Muravin A.I., Boiko A.N., Popova E.V., Murashko A.V. Effect of pregnancy on the course of multiple sclerosis. Med. sovet. 2015; 7: 23–7 (in Russian).
Авторы
А.Д. Купина, Ю.А. Петров*
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России, Ростов-на-Дону, Россия
*mr.doktorpetrov@mail.ru
Rostov State Medical University, Rostov-on-Don, Russia
*mr.doktorpetrov@mail.ru
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России, Ростов-на-Дону, Россия
*mr.doktorpetrov@mail.ru
________________________________________________
Rostov State Medical University, Rostov-on-Don, Russia
*mr.doktorpetrov@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.